Health Canada Adds Submission Class Data to Public Tracker
Health Canada has enhanced its public drug review tracking system by adding submission 'class' information, including whether applications were reviewed under the Access Consortium framework, as of March 20, 2026.
New Transparency Features
The updated Drug and Health Product Submissions Under Review (SUR) system now provides Canadians with additional details about how their medications are being evaluated. The submission class designation helps distinguish between different types of regulatory pathways used for drug approvals.
This enhancement comes as Health Canada processes nine generic semaglutide applications, making the review process more transparent for patients and healthcare providers tracking these submissions.
Access Consortium Integration
The new system specifically identifies submissions reviewed under the Access Consortium, an international regulatory cooperation initiative. This partnership allows Health Canada to leverage reviews conducted by regulatory agencies in Australia, Singapore, Switzerland, and the United Kingdom.
For generic GLP-1 medications currently under review, this classification system helps stakeholders understand which regulatory pathway each application follows and potentially predict review timelines.
Impact on Generic Reviews
The timing of this transparency update coincides with significant activity in Canada's generic drug pipeline. Companies including Sandoz, Apotex, Teva, and others have submitted applications for generic versions of popular medications like Ozempic and Wegovy.
The enhanced tracking system allows patients to monitor these applications through Health Canada's 180-day review timeline with greater clarity about the regulatory process being used.
Public Access Benefits
Healthcare professionals and patients can now access more detailed information about:
- Submission classification categories
- Access Consortium review designations
- Regulatory pathway distinctions
- International cooperation frameworks
This information complements existing features on the generic semaglutide tracker and helps Canadians better understand the drug approval process.
Regulatory Context
Health Canada's move toward greater transparency reflects growing public interest in drug approval processes, particularly for high-demand medications. The agency continues to update its systems as it reviews applications for Mounjaro and other GLP-1 medications.
Patients seeking information about coverage options can consult the insurance coverage checker or review common questions in the FAQ section.
This article is for informational purposes only and does not constitute medical advice.
Get notified when generic prices go live
We’ll send one email the moment generic semaglutide prices are listed at Canadian pharmacies. No spam.
Get notified when generic semaglutide becomes available in Canada
Expected Q3 2026 — be the first to know
